Private Equity Firms to Acquire PPD for $3.9 Billion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Private Equity Firms to Acquire PPD for $3.9 Billion


ePT--the Electronic Newsletter of Pharmaceutical Technology

The CRO Pharmaceutical Product Development (PPD) will be acquired by the Carlyle Group and Hellman and Friedman in a deal valued at approximately $3.9 billion. PPD shareholders will receive $33.25 per share in cash, and PPD will become a privately held company after completion of the transaction. PPD employs more than 11,000 people worldwide and provides contract preclinical and clinical development services to the pharmaceutical and biotechnology sectors.

The Carlyle Group is a global alternative asset manager, and Hellman and Friedman is a private equity firm. Funding for the deal will come from the two companies, along with external debt financing commitments provided by Credit Suisse, JP Morgan, Goldman Sachs, and UBS. The transaction is expected to close in the fourth quarter of 2011.

“Fred Eshelman and PPD’s management team have built a leading and extremely high-quality global research and services organization that will continue to help pharmaceutical and biotech companies develop new drugs at lower costs,” said Karen H. Bechtel, managing director and head of the healthcare group at Carlyle, in a press release. “We look forward to helping expand and enhance PPD’s platform and broad spectrum of therapeutic expertise.”


See related Pharm Tech articles:

PPD Appoints Raymond Hill as CEO (ePT)

What to Watch For in 2011 (Pharm Tech)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here